ÂÜÀòÂÒÂ×

Byron Robinson (PhD, JD) brings 30 years of extensive management and drug development expertise to his role as Chief Strategy Officer at Janux. Prior to joining Janux, he served as the Senior Vice President of Clinical Development Strategy and Innovation at Merck KGaA. In this role he was responsible for generating strategic insights for internal and external innovation for the generation of the Clinical Oncology Franchise Strategy for all Merck KGaA Oncology assets. In addition, he also served as the Senior Vice President Global Program Leader for the Avelumab program, where he advanced Bavencio® through late-stage development, including eleven registrational Phase 3 trials, and over 240 clinical trials.

Prior to Merck KGaA, he worked as Vice President, Senior Global Program Head (GPH), Oncology (Early & Late) at Bayer Health Care, developing several assets including Aliqopa® (Copanlisib) in the heme and solid tumor space. Prior to Bayer, he worked at both Amgen Thousand Oaks as a Global Project Manager on seventeen different assets across multiple therapeutic areas, including Aranesp® and Epogen® and at Miravant Medical Technologies in Santa Barbara where he was the Head of Chemistry Research and Development.

Byron earned his BSc. (Honors I) and PhD in organic chemistry from the University of New England, Armidale, Australia and completed his JD from Santa Barbara College of law.